| Sep 26 |
AbbVie Parkinson's disease therapy hits main goal in late-stage trial
|
| Sep 26 |
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
|
| Sep 26 |
AbbVie's Parkinson's disease drug meets main goal in late-stage trial
|
| Sep 26 |
AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
|
| Sep 26 |
AbbVie and SpinUp Foster Canadian Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award
|
| Sep 26 |
AbbVie’s RINVOQ shows promise in two Phase III atopic dermatitis trials
|
| Sep 25 |
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
|
| Sep 25 |
AbbVie Rinvoq shows effectiveness for atopic dermatitis in head and neck
|
| Sep 25 |
Exploring Three High Growth Tech Stocks in the United States
|
| Sep 25 |
New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
|
